Publications
-
A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness
Citation: Stein JH, Ribaudo, HJ, Hodis, HN, Brown TT, Tran TTT, Yan M, Lauer-Brodell E, Kelesidis T, McComsey GA, Dubé, MP, Murphy RL, Currier, JS. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015 Sep 10;29(14):1775-83. doi: 10.1097/QAD.0000000000000762. PMID: 26372383. PMCID: PMC4571277
Date: 09/10/2015
Heterogeneity of T cell responses to pandemic pH1N1 monovalent vaccine in HIV-infected pregnant
Citation: Weinberg A, Muresan P, Richardson K, Fenton T, Dominguez T, Bloom A, Watts DH, Abzug MJ, Nachman SA, Levin MJ; P1086 Study Team. Heterogeneity of T cell responses to pandemic pH1N1 monovalent vaccine in HIV-infected pregnant women. AIDS Res Hum Retroviruses. 2015 Nov;31(11):1170-7. doi: 10.1089/aid.2015.0151. Epub 2015 Aug 31. PMID: 26322930; PMCID: PMC4651022
Date: 08/31/2015
Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1
Citation: Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC Jr, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P; ALLY-2 Investigators.Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015 Aug 20;373(8):714-25. doi: 10.1056/NEJMoa1503153. Epub 2015 Jul 21. PMID: 26196502.
Date: 08/20/2015
Perceptions of community HIV/STI risk among US women living in areas with high poverty and HIV
Citation: Blackstock OJ, Frew P, Bota D, Vo-Green L, Parker K, Franks J, Hodder SL, Justman J, Golin CE, Haley DF, Kuo I, Adimora AA, Rompalo A, Soto-Torres L, Wang J, Mannheimer SB. PPerceptions of community HIV/STI risk among US women living in areas with high poverty and HIV prevalence rates. J Health Care Poor Underserved. 2015 Aug;26(3):811-23. doi: 10.1353/hpu.2015.0069.
Date: 08/15/2015
Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based
Citation: Kelesidis T, Tran TTT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dubé MP, Murphy RL, Yang O, Currier JS, McComsey GA. Changes in inflammation and immune activation with atazanavir-, raltegravir, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis. 2015 Aug 15;61(4):651-60. doi: 10.1093/cid/civ327. PMID: 25904376. PMCID: PMC4542595.
Date: 08/15/2015
Regimen selection in the OPTIONS trial of HIV salvage therapy: Drug resistance, prior therapy, and
Citation: Tashima KT, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, Andrade A, Johnson VA, Eron JJ, Smeaton L, Haubrich RH. Regimen selection in the OPTIONS trial of HIV salvage therapy: Drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. HIV Clin Trials. 2015 Aug;16(4):147-56. doi: 10.1179/1945577115Y.0000000001. Epub 2015 Jul 27. PMID: 26212575. PMCID: PMC4640927.
Date: 08/15/2015
Sexual Behaviors of US Women at Risk of HIV Acquisition: A Longitudinal Analysis of Findings from
Citation: Justman J, Befus M, Hughes J, Wang J, Golin CE, Adimora AA, Kuo I, Haley DF, Del Rio C, El-Sadr WM, Rompalo A, Mannheimer S, Soto-Torres L, Hodder S. Sexual Behaviors of US Women at Risk of HIV Acquisition: A Longitudinal Analysis of Findings from HPTN 064. AIDS Behav. 2015 Jul;19(7):1327-37. doi: 10.1007/s10461-014-0992-8. PMID: 25626889; PMCID: PMC4506244
Date: 07/15/2015
Contraceptive use and factors associated with postpartum surgical sterilization among HIV-infected
Citation: Suryavanshi N, Mave V, Gupte N, Bhosale R, Sambarey P, Patil S, Sastry J, Bollinger R, Gupta A, Shankar A & The SWEN India Study Team. Contraceptive use and factors associated with postpartum surgical sterilization among HIV-infected women in Pune, India. Journal of HIV/AIDS and Social Services. 2015 Jul 3;14(3):359-370. DOI: 10.1080/15381501.2014.946548.
Date: 07/03/2015
High-dose Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: A
Citation: Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne K, Napoli A, Hardin WR, Ribaudo HJ, Yin MT. High-dose Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: A randomized trial. Ann Intern Med. 2015 Jun 16;162(12):815-24. PMID: 26075752. PMCID: PMC4608553.
Date: 06/16/2015
Comparison of the metabolic effects of ritonavir boosted darunavir or atazanavir versus raltegravir,
Citation: Ofotokun I, MD, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, MD, Seekins D, Baugh BP, Rooney JF, Lennox JL, Currier JS. Comparison of the metabolic effects of ritonavir boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 Jun 15;60(12):1842-51. PMID: 25767256. PMCID: PMC4660025.
Date: 06/15/2015
- ‹ First < 15 16 17 18 19 > Last ›